Biogen Adds Pfizer’s PF-05251749 to its Neuroscience Pipeline in US$710 M Deal

By Neha Madhwani

Pharma Deals Review: Vol 2020 Issue 2 (Table of Contents)

Published: 4 Feb-2020

DOI: 10.3833/pdr.v2020.i2.2511     ISSN: 1756-7874

Section: Mergers & Acquisitions



Biogen has agreed to acquire Pfizer’s PF-05251749, a Phase I asset in development for the treatment of Alzheimer’s disease (AD) and Parkinson’s disease (PD), in exchange for US$75 M upfront...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details